Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel이스라엘 의료 종사자의 2차 BNT162B2 백신 접종 후 1개월 및 3개월 후의 면역원성 경향Article Published on 2022-03-012022-09-12 Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 진단, [키워드] 95%CI acute respiratory syndrome addition adjusted age allergic reaction Analysis anti-spike antibody antibodies antibody BNT162b2 booster dose coronavirus COVID-19 evaluated Factor HCW HCWs healthcare worker Healthcare workers identify IgG illnesses immunogenicity Immunosuppressive treatment LIAISON Linear model Male sex medications MOST multivariate not correlated Older age participant predict prospective cohort study questionnaire Rash S1/S2 SARS-CoV-2 serology significantly lower tested the antibody response Treatment vaccination Vaccine vaccine administration vaccine dose [DOI] 10.1016/j.cmi.2021.11.014 PMC 바로가기 [Article Type] Article
An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates아랍에미리트의 투석 환자에서 Sinopharm HB02 COVID19 백신의 항체 반응 및 임상 후유증 분석Article Published on 2022-03-012022-09-11 Journal: Nephrology (Carlton, Vic.) [Category] SARS, 변종, [키워드] adverse events Analysis anti-spike antibodies anti-spike antibody antibodies antibody Antibody Response Antibody responses appear baseline booster dose Case fatality rate Clinical effect Cohort Course COVID COVID-19 COVID-19 vaccination COVID19 dialysis dose examined Fatality rate General population Haemodialysis haemodialysis patients humoral immune response humoral immune responses Humoral response humoral responses immune responses individuals Infection occur Patient patients positive PROTECT reduction in response Side-effects Sinopharm Standard survival the antibody response the vaccine to define United Arab Emirate vaccination vaccination schedule Vaccine were given [DOI] 10.1111/nep.13980 PMC 바로가기 [Article Type] Article
Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents이전 SARS-CoV-2 감염, 연령 및 노쇠는 요양원 거주자의 6개월 백신 유도 항스파이크 항체 역가와 관련이 있습니다Article Published on 2022-03-012022-09-11 Journal: Journal of the American Medical Directors Associat [Category] MERS, SARS, 진단, 치료법, [키워드] 95% confidence interval ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age All participant All participants analyzed angiotensin Angiotensin-converting enzyme Anti-spike anti-spike antibody antibody Antibody Response Antibody titer Antibody titers BNT162b2 Clinical outcome clinical outcomes cohort study Comorbidity Comprehensive coronavirus correlated COVID-19 demonstrated determinant determinants Evidence evidence of examined female frailty home in vitro independent of Infection log-transformed Long-term care longitudinal longitudinal cohort study make up Messenger RNA morbidity morbidity and mortality naïve Neutralization assay neutralization capacity nucleocapsid Nursing nursing home nursing homes Older participant post vaccination RBD receptor Receptor binding domain resident respiratory risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2.0 Serum Neutralization setting severe acute respiratory syndrome Coronavirus significantly significantly lower the strongest timepoints titer vaccination Vaccine vulnerable population was performed [DOI] 10.1016/j.jamda.2021.12.001 PMC 바로가기 [Article Type] Article
Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis투석 중인 환자의 mRNA-1273(모더나)과 BNT162b2(화이자-바이오엔텍) SARS-CoV-2 백신 면역원성의 차이Observational Study Published on 2022-02-282022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), SARS, 임상, 치료법, [키워드] anti-RBD Anti-spike anti-spike antibody antibody BNT162b2 Canada characterized conducted Control convalescent convalescent serum dialysis difference dose elicited Hemodialysis humoral immunogenicity Immunoglobulin Immunoglobulin G infected with SARS-CoV-2 Maintenance hemodialysis Moderna mRNA mRNA-1273 nucleocapsid protein Patient Pfizer-BioNTech populations prospective observational cohort reached Receptor binding domain recommendation SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose second dose of vaccine Serologic response significantly lower Spike protein the median the spike protein Toronto vaccination Vaccine [DOI] 10.1503/cmaj.211881 PMC 바로가기 [Article Type] Observational Study
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission Research Published on 2022-02-232022-10-05 Journal: NPJ Vaccines [Category] 변종, 임상, 치료기술, [키워드] Administered anti-spike antibody approach B.1.617.2 characterized Complete COVID-19 vaccine D614G effective elicited hamsters humoral induce Infection intramuscularly mice monomeric naïve neutralizing antibody offer prevented provide provided RBD Recombinant protein Recombinant spike protein Safe SARS-COV-2 infection SARS-CoV-2 spike protein spike receptor-binding domain subunit T-cell Response Transmission Vaccine variants Viral transmission wild-type [DOI] 10.1038/s41541-022-00450-8 [Article Type] Research
Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail PopulationArticle Published on 2022-02-082022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Analysis analyzed anti-SARS-CoV-2 anti-spike antibody antibodies antibody Antibody titer BNT162b2 vaccine cellular immunity Cellular responses controls correlation COVID-19 determine dose Efficacy Evidence flow cytometry General population humoral immune marker indicated individual individuals Infection interferon gamma measure median age neutralization titer non-responder nursing home parameter Population proportion response SARS-CoV-2 secretion sera serum serum neutralization titer significant decrease spike IgG susceptibility Testing vaccination virus [DOI] 10.3390/vaccines10020260 PMC 바로가기 [Article Type] Article
Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence회복기 동안 경증 COVID-19 외래 환자의 지속적인 항체 의존성 NK 세포 기능Immunology Published on 2022-02-072022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome addition Anti-spike anti-spike antibody anti-viral response antibody blood sample Cell characterized Cohort collected contribute convalescence coronavirus coronavirus disease correlated COVID-19 COVID-19 outpatients COVID19 defined disease Fc-effector functions female function heterogeneous humoral Humoral response identify IgA IgG titers immune correlate male natural killer neutralization NK cells activity Outpatient outpatients pandemic profile researcher response responses SARS-CoV-2 severity spike (S) glycoprotein Spike protein sustained the SARS-CoV-2 Virus neutralization while [DOI] 10.3389/fimmu.2022.796481 PMC 바로가기 [Article Type] Immunology
Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study인도 의료 종사자들 사이에서 ChAdOx1-nCOV(Covishield™) 및 BBV-152(Covaxin™) 백신을 사용한 체액 항체 동역학: 6개월 종단면 코로나바이러스 백신 유도 항체 역가(COVAT) 연구Article Published on 2022-02-012022-09-12 Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Analysis anti-spike antibody antibody Antibody Response Antibody titer Antibody titre Blood Group body-mass cohorts Comorbidity conducted Covaxin COVID-19 Covishield cross-sectional Decline decrease dose Gender geometric mean GMT healthcare worker humoral humoral antibody Humoral response individual individuals Infection linear mixed model no difference participant Participants Quantitative recipient SARS-CoV-2 second dose Seropositivity significantly higher significantly more type 2 diabete Vaccine Vaccines were used [DOI] 10.1016/j.dsx.2022.102424 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal DialysisObservational Study Published on 2022-02-012022-10-05 Journal: American journal of kidney diseases : the official [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome Adverse adverse effects anti-SARS-CoV-2 Anti-spike anti-spike antibody anti-spike serology antibody antibody levels Antibody titer BNT162b2 BNT162b2 vaccine booster booster dose characterized Clinical outcome coronavirus coronavirus disease Coronavirus disease 2019 (COVID-19) dialysis dose End-stage renal disease End-stage renal disease (ESRD) evaluated event French General population greater Hemodialysis humoral Humoral response immune immune response Immunoglobulin increase in initial IQR maintenance median median age men observational study Patient patients treated Peritoneal dialysis plasma produced rationale receiving recent relationship Responder response SARS-CoV-2 second dose setting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) single center small sample size Spike protein Third booster dose treated vaccination Vaccine vaccine adverse effects. vaccine dose [DOI] 10.1053/j.ajkd.2021.08.005 PMC 바로가기 [Article Type] Observational Study
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα항-TNFα 치료를 받은 염증성 장 질환 환자의 코로나19 mRNA 백신에 대한 혈청학적 반응 감소Observational Study Published on 2022-02-012022-09-11 Journal: Gastroenterology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] administration adverse event adverse events AEs all subject all subjects Anti-spike anti-spike antibody anti-TNF antibody BNT162b2 booster dose comparable coronavirus disease COVID-19 dose doses drug level drug levels enrolled function functional groups HCs healthy control healthy controls high risk IBD infection rate infections Inflammatory bowel disease inflammatory bowel diseases inhibitory Lower magnitude Messenger RNA mounted mRNA mRNA-BNT162b2. multicenter Necrosis not affect Patient patients treated Pfizer Pfizer/BioNTech Prospective Prospective Study remained response Safe safety profile second dose serologic Serologic response serologic responses seronegative seropositive significantly lower stratified therapy TNFα treated treated patients Treatment Vaccine vaccine dose vaccine response vaccine responses [DOI] 10.1053/j.gastro.2021.10.029 PMC 바로가기 [Article Type] Observational Study